Interested in promotions? | Click here >>
Human Vascular Endothelial Growth Factor-165 (hVEGF165 )
Growth Factors and Cytokines

Human Vascular Endothelial Growth Factor-165 (hVEGF165 ) #8065

Reviews ()
Citations (3)
Human Vascular Endothelial Growth Factor-165 (hVEGF165 ): Image 1

The proliferation of HUVEC treated with increasing concentrations of hVEGF165 was assessed. After 72-hour treatment with hVEGF165 cells were incubated with a tetrazolium salt and the OD450 - OD650 was determined.

Human Vascular Endothelial Growth Factor-165 (hVEGF165 ): Image 2

The purity of recombinant hVEGF165 was determined by SDS-PAGE of 6 µg reduced (+) and non-reduced (-) recombinant hVEGF165 and staining overnight with Coomassie Blue.

Human Vascular Endothelial Growth Factor-165 (hVEGF165 ): Image 3

Western blot analysis of extracts from HUVEC untreated or treated with hVEGF165 for 15 minutes, using Phospho-p38 MAPK (Thr180/Tyr182) (3D7) Rabbit mAb #9215 (upper) and p38 MAPK Antibody #9212 (lower).


With carrier: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 20 μg BSA per 1 μg hVEGF165. Carrier free: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2.


Stable in lyophilized state at -20°C for 1 year after receipt. Sterile stock solutions reconstituted with carrier protein are stable at 4°C for 2 months and at -20°C for 6 months. Avoid repeated freeze-thaw cycles.Maintain sterility. Storage at -20°C should be in a manual defrost freezer.

Product Description

MW (kDa) 26

>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hVEGF165. All lots are greater than 98% pure.


Less than 0.01 ng endotoxin/1μg hVEGF165.


The bioactivity of recombinant hVEGF165 was determined in a cell proliferation assay using HUVEC. The ED50 of each lot is between 1-6 ng/ml.

Molecular Formula

Recombinant hVEGF165 contains no "tags" and has a calculated MW of 19,165. DTT-reduced protein migrates as a 24 kDa polypeptide and the non-reduced cystine-linked homodimer migrates as a 40 kDa protein. The expected amino-terminal APMAE of recombinant hVEGF165 was verified by amino acid sequencing.

Source / Purification

Recombinant human VEGF165 (hVEGF165) Ala207-Arg371 (Accession #NP_001020539) was expressed in human 293 cells at Cell Signaling Technology.


VEGF165 is the most abundant splice variant of VEGF-A (1,2). VEGF165 is produced by a number of cells including endothelial cells, macrophages and T cells. VEGF165 is involved in angiogenesis, vascular endothelial cell survival, growth, migration and vascular permeability (1). VEGF gene expression is induced by hypoxia, inflammatory cytokines and oncogenes (1,2). VEGF165 binds to heparan sulfate and is retained on the cell surface and in the extracellular matrix (2,3). VEGF165 binds to the receptor tyrosine kinases, VEGFR1 and VEGFR2 (1). VEGF165 is the only splice variant that binds to co-receptors NRP-1 and NRP-2 (1-3) that function to enhance VEGFR2 signaling (1). Binding of VEGF165 to VEGFR1 and VEGFR2 leads to activation of the PI3K/AKT, p38 MAPK, FAK and paxillin (1). VEGF plays a key role in tumor angiogenesis in many cancers (2).

  1. Takahashi, H. and Shibuya, M. (2005) Clin Sci (Lond) 109, 227-41.
  2. Neufeld, G. et al. (1999) FASEB J 13, 9-22.
  3. Robinson, C.J. and Stringer, S.E. (2001) J Cell Sci 114, 853-65.

Pathways & Proteins

Explore pathways + proteins related to this product.

Limited Uses

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST's products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST's Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.

For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
To Purchase # 8065SC
Product # Size Price
10 µg  (With Carrier) $ 227